Corcept Therapeutics Incorporated. Stock News

Corcept Therapeutics Incorporated (CORT) shares rise on treatment advances, Big Money buys.

NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Inc. (NASDAQ: CORT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Corcept's sole drug, Korlym, treats Cushing Syndrome, a more prevalent condition than previously known, driving strong revenue and profit growth. A new market for Corcept's medications, diabetics, is poised to take the company to the next level. Long-term goal is $3 billion revenue by 2029, driven by the new drug Relacorilant, which could expand market reach beyond Korlym.

Corcept Therapeutics makes drugs that modulate cortisol. The post Medical Stock Soars To Highs As Cortisol Screening Grows appeared first on Investor's Business Daily.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its prop...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its Phase 3 long-term, open-label extension study of relacorilant to trea...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the primary endpoint was met in the treatment phase of CATALYST, a randomiz...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.